These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35339752)

  • 21. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
    Ferri N; Corsini A; Macchi C; Magni P; Ruscica M
    Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
    Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy.
    Xu M; Lei G; Chen M; Wang K; Lv W; Zhang P; Hu T; Gao J; Lu C; Mei Y; Xu Z; Bai Z; Hu H; Jiang Y; Tan S
    EBioMedicine; 2021 Mar; 65():103250. PubMed ID: 33647772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice.
    Kawakami R; Nozato Y; Nakagami H; Ikeda Y; Shimamura M; Yoshida S; Sun J; Kawano T; Takami Y; Noma T; Rakugi H; Minamino T; Morishita R
    PLoS One; 2018; 13(2):e0191895. PubMed ID: 29438441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of PCSK9 monoclonal antibodies.
    Iqbal Z; Dhage S; Mohamad JB; Abdel-Razik A; Donn R; Malik R; Ho JH; Liu Y; Adam S; Isa B; Stefanutti C; Soran H
    Expert Opin Drug Saf; 2019 Dec; 18(12):1191-1201. PubMed ID: 31623472
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
    Liberale L; Montecucco F; Camici GG; Dallegri F; Vecchie A; Carbone F; Bonaventura A
    Curr Med Chem; 2017; 24(14):1403-1416. PubMed ID: 28260498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proprotein convertase subtilisin/kexin type 9 and lipid metabolism.
    Spolitu S; Dai W; Zadroga JA; Ozcan L
    Curr Opin Lipidol; 2019 Jun; 30(3):186-191. PubMed ID: 30925519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9 Biology and Its Role in Atherothrombosis.
    Barale C; Melchionda E; Morotti A; Russo I
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
    Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M
    Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.
    Chan JC; Piper DE; Cao Q; Liu D; King C; Wang W; Tang J; Liu Q; Higbee J; Xia Z; Di Y; Shetterly S; Arimura Z; Salomonis H; Romanow WG; Thibault ST; Zhang R; Cao P; Yang XP; Yu T; Lu M; Retter MW; Kwon G; Henne K; Pan O; Tsai MM; Fuchslocher B; Yang E; Zhou L; Lee KJ; Daris M; Sheng J; Wang Y; Shen WD; Yeh WC; Emery M; Walker NP; Shan B; Schwarz M; Jackson SM
    Proc Natl Acad Sci U S A; 2009 Jun; 106(24):9820-5. PubMed ID: 19443683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
    Pokrywka GS
    Postgrad Med; 2018 Apr; 130(3):287-298. PubMed ID: 29411675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.
    Julius U; Tselmin S; Schatz U; Fischer S; Bornstein SR
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):45-50. PubMed ID: 30838555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors.
    Eisen A; Giugliano RP
    Curr Opin Cardiol; 2016 Nov; 31(6):644-653. PubMed ID: 27661220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.